BioDura-Sundia and X-Chem partner for DEL services in China

169
Dr. Xiang Li, Drug Discovery President of BioDuro-Sundia. Source https://bioduro-sundia.com/

US based BioDuro-Sundia, one of the industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and US headquartered X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its powerful DEL technology platform and large collection of novel, diverse lead- and drug-like small molecule compounds to help customers significantly accelerate the discovery of hits and expand their target range. Combined with BioDuro-Sundia’s drug discovery platform, customers can access world-class discovery technologies and support, covering hit identification and optimization, evaluation of lead and candidate compounds, and quickly advance to preclinical development.

As a pioneer in DEL technology, X-Chem’s libraries contain over 250 billion small molecules. X-Chem has licensed more than 100 research projects to companies in the US, Europe and Japan, comprising over three hundred independent chemical series and more than one thousand validated hit compounds. BioDuro-Sundia will utilize its powerful protein screening platform to assist customers to complete the protein qualification, ensuring that its purity, concentration and degree of aggregation meet the requirements for compound library screening to ensure the best chances for hit identification.

“We are very pleased to collaborate with BioDuro-Sundia in China to explore more new and challenging, valuable therapeutic targets,” said X-Chem ‘s CBO, Steffen Helmling. “We believe that X-Chem’ s DEL platform technology, in strong association with BioDuro-Sundia’s one-stop new drug discovery development platform, can deliver promising drug leads and will bring higher value returns to our biopharma clients.”

“We look forward to working with X-Chem to help our customers discover more novel small molecule leads through the application of DNA Encoded Compound Library (DEL),” said Dr. Xiang Li, Drug Discovery President of BioDuro-Sundia. “This collaboration will provide a cutting-edge platform for hit identification in early drug discovery and further expand BioDuro-Sundia’s one-stop new drug discovery and development capabilities. It will also empower innovative Chinese pharmaceutical companies with a more efficient drug discovery mechanism. We believe that through our collaboration with X-Chem scientists, new drug candidates will continue to be discovered and advanced, eventually moving towards the clinic and benefiting patients.”

Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here